Intelsat Unveils Terminal Strategy to Power Multi-Orbit Satellite Services
Intelsat, operator of one of the world’s largest integrated satellite and terrestrial networks and leading provider of in-flight connectivity (IFC), will be the first operator in the world to offer multi-orbit solutions for all relevant business units by the first half of 2025 thanks to a new satellite terminal strategy that will deliver advanced capabilities and improved economics.
“Intelsat is making strategic bets on new technologies, including new investments in innovative terminal providers,” said Intelsat CEO David Wajsgras. “More and more customers will come to count on the broad reliability profile of multi-orbit solutions, and it is key to our future success. No single-orbit solution can match what Intelsat can offer when it comes to performance, resiliency and commercial flexibility.”
Intelsat has an unmatched network of geostationary satellites as well as partnerships with low Earth orbit providers. With the launch of a new robust terminal strategy, Intelsat is now able to deliver multi-orbit managed-service solutions across all relevant verticals including commercial aviation, government and mobility applications.
“Intelsat began the process of delivering operational multi-orbit terminals to the military and commercial airlines about two years ago,” Wajsgras said. “Today, our multi-orbit strategy is resonating with customers and validating our approach.”
The Intelsat multi-orbit terminal strategy includes minority investments with a few cutting-edge terminal providers. Intelsat recently invested in Paris-based Greenerwave and signed a technology agreement to develop an innovative electronically-steerable antenna that will be integrated into high throughput, multi-orbit terminals for Network and Data applications, as well.
Fast switching between multiple networks and multiple orbits, Greenerwave’s Electronically Steered Array (ESA) terminal will include Intelsat custom features to deliver unmatched reliability and performance for a differentiated connectivity experience for broadband, mobility, media and government customers, globally.
“Strategic investments with terminal providers allow us to work in partnership to bring these technologies to market faster while delivering a step change in the customer experience,” Wajsgras said.
The new scalable terminal will be available as part of the Intelsat’s Managed Service offerings, high-throughput, reliable connectivity without the worry and hassle of managing a satellite network. This new terminal combines flexible beamforming, real-time reconfiguration, and low-power consumption. A key innovation includes smaller dimensions that features interleaved receivers and transmitters on a single antenna panel. The antenna can operate as either a half-duplex or full-duplex terminal based on requirements, all while reducing the panel size by up to 50%.
About Intelsat
Intelsat’s global team of professionals is focused on providing seamless and secure, satellite-based communications to government, NGO and commercial customers through the company’s next-generation worldwide network and managed services. Bridging the digital divide by operating one of the world’s largest and most advanced satellite fleet and connectivity infrastructures, Intelsat enables people and their tools to speak over oceans, see across continents and listen through the skies to communicate, cooperate and coexist. Since its founding six decades ago, the company has been synonymous with satellite-industry “firsts” in service to its customers and the planet. Leaning on a legacy of innovation and focusing on addressing a new generation of challenges Intelsat team members now have their sights on the “next firsts” in space as they disrupt the field and lead in the digital transformation of the industry.
About Greenerwave
Greenerwave is an industrial deeptech founded in 2015 by researchers Geoffroy Lerosey and Mathias Fink, spin-off from the Langevin Institute, dependent on CNRS and ESPCI-PSL (École supérieure de physique et de chimie industrielles de Paris). Specializing in the control and orientation of electromagnetic waves, Greenerwave designs and develops, in France, a revolutionary technology that drastically improves the energy efficiency of equipment, making it more economical, more environmentally friendly and less dependent on semi-conductors. This disruptive technology is finds application across various sectors, ranging from the automotive industry to satellite communications and the Internet of Things.
To learn more, please visit www.greenerwave.com
Follow Us on Social Media:
Twitter/X https://twitter.com/INTELSAT
LinkedIn https://www.linkedin.com/company/intelsat
Instagram https://www.instagram.com/intelsat/?hl=en
YouTube https://www.youtube.com/user/intelsatmedia
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916165105/en/
Contacts
Melissa Longo - melissa.longo@intelsat.com; +1 240-308-1881
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press Release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press Release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press Release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press Release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom